We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Test Aids Diagnosis of Preeclampsia

By LabMedica International staff writers
Posted on 09 Jan 2013
A test with high sensitivity and specificity level helps diagnosis of early onset preeclampsia.

The triage placental growth factor (PLGF) test is a fluorescence immunoassay, which, when used in conjunction with a Triage Meter enables the quantitative determination of PLGF in ethylenediaminetetraacetic acid (EDTA) anticoagulated plasma samples. More...
Together with other diagnostic and clinical information, the test aids in the diagnosis of preeclampsia.

The Alere (Linz, Austria) Triage PLGF test can provide a PLGF level from a maternal plasma specimen in just 15 minutes. The Triage MeterPro is a portable fluorescence instrument used to measure the results of the Triage tests from Alere. The Triage MeterPro can be used in a laboratory or in a point-of-care setting. It uses a Class 1 laser as a light source. Light from the laser hits a test device that has been inserted in the meter. This causes the fluorescent dye in the test device to give off energy. The more energy the fluorescent dye gives off, the stronger the signal.

The current criteria for defining preeclampsia (raised blood pressure and protein in urine) are nonspecific, appear late in the development of the disease, and result in over diagnosis because of their poor specificity.

On December 15, 2011, the Lancet published an editorial online that highlights the fact that many maternal deaths in the UK are associated with substandard care and are potentially preventable. The article suggests that it is the failure to diagnose or appropriately manage preeclampsia, which is the most common cause of maternal death.

Preeclampsia is a serious and potentially fatal condition that arises in pregnancy, usually in the second or third trimester. The exact cause is unknown but it is thought to be related to a problem with the placenta. The nonspecificity of signs and symptoms contribute to making clinical diagnosis a significant challenge, this represents a high risk to both mother and child.

Prof. Christopher Redman, emeritus professor of Obstetrics at John Radcliffe Hospital (Oxford, United Kingdom) commented, “A reliable and specific test that aids in the diagnosis of those aspects of the preeclampsia syndrome that jeopardize the safety of mother and/or unborn baby would be invaluable. Alere Triage PLGF is a major advance in the assessment for preterm disease.”

Related Links:
Alere
John Radcliffe Hospital


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Calprotectin Assay
Fecal Calprotectin ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.